Agmatine relieves behavioral impairments in Fragile X mice model

CONCLUSIONS: The results highlight the potential of agmatine's novel disease-ameliorating effects in FXS, which warrants further studies to ascertain whether these findings translate into clinical effects in FXS patients.PMID:36057317 | DOI:10.1016/j.neuropharm.2022.109234

Source: Neuropharmacology - September 3, 2022 Category: Drugs & Pharmacology Authors: Se Jin Jeon Huiyoung Kwon Ho Jung Bae Edson Luck Gonzales Junhyeong Kim Hye Jin Chung Dong Hyun Kim Jong Hoon Ryu Chan Young Shin Source Type: research